# CPLX1 Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- The *CPLX1* gene encodes complexin-1, a crucial regulator of synaptic vesicle exocytosis that binds to the SNARE complex to modulate neurotransmitter release. Its primary molecular function is SNARE binding, essential for both clamping spontaneous fusion and facilitating calcium-triggered release.
- *CPLX1* is located at chromosomal locus 4p16.3 and is predominantly expressed in the central nervous system, with significant roles in neuronal function and implicated in various neurological disorders.
- Mutations or deletions in *CPLX1* are associated with severe conditions such as Dravet syndrome (epileptic encephalopathy) and contribute to the neurological phenotype of Wolf-Hirschhorn syndrome, leading to neuronal hyperexcitability and developmental deficits.
- Dysregulation of *CPLX1* expression is linked to neurodegenerative diseases like Parkinson's disease and Alzheimer's disease, as well as psychiatric disorders including schizophrenia, where it is a validated target of the risk microRNA miR-137.
- Beyond neuroscience, *CPLX1* plays a role in pancreatic β-cell insulin secretion and is implicated in the pathogenesis and prognosis of several cancers, including gastric and colorectal cancer, and inflammatory conditions like Behçet's disease.
- Complexin-1's function is modulated by post-translational modifications such as phosphorylation by PKC and CaMKII, and its interaction network includes key synaptic proteins like synaptotagmin-1 and α-synuclein, highlighting its central role in synaptic transmission and disease.

---

## Executive Summary & Key Metadata

The *CPLX1* gene encodes complexin-1, a small cytosolic protein that functions as a critical regulator of synaptic vesicle exocytosis. Complexin-1 binds with high affinity to the soluble N-ethylmaleimide-sensitive factor attachment protein receptor (SNARE) complex, modulating the precisely timed release of neurotransmitters at chemical synapses. Beyond its canonical role in neurotransmission, CPLX1 has been implicated in a spectrum of human pathologies ranging from severe epileptic encephalopathies to psychiatric disorders and various malignancies. The following table summarizes the essential genomic and proteomic identifiers for CPLX1.

| **Attribute** | **Value** |
|:---|:---|
| **HGNC Symbol** | CPLX1 |
| **UniProt Accession** | O14810 |
| **Representative PDB ID** | 1KIL (and related SNARE-complex structures) |
| **Chromosomal Locus** | 4p16.3 |
| **Primary Molecular Function** | SNARE complex binding; regulation of synaptic vesicle fusion and neurotransmitter release |
| **Disease & Pathology Associations** | Dravet syndrome (epileptic encephalopathy), schizophrenia, Parkinson's disease, essential tremor, Wolf-Hirschhorn syndrome, gastric cancer, colorectal cancer, glioblastoma, Behçet's disease |

The gene is highly conserved across metazoans, reflecting its fundamental role in calcium-triggered exocytosis. CPLX1 is predominantly expressed in the central nervous system (CNS), with particularly high levels in the hippocampus, cerebellum, and cerebral cortex, though expression has also been documented in pancreatic β-cells and various tumor tissues.

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Localization and Gene Structure

The *CPLX1* gene is located on the short arm of chromosome 4 at cytogenetic band 4p16.3. This genomic region is notable for its gene density and its association with several developmental disorders, most prominently Wolf-Hirschhorn syndrome (WHS), which results from contiguous gene deletions in this region [1, 2, 3]. The gene spans approximately 6.5 kilobases (kb) of genomic DNA on the plus strand. The precise coordinates, based on the GRCh38/hg38 human genome assembly, are approximately chr4:784,957–791,500.

The genomic architecture of *CPLX1* is relatively compact, comprising five exons and four introns. The coding sequence is distributed across all five exons, with the translation initiation codon located in exon 1 and the termination codon in exon 5. The 5' untranslated region (UTR) is short, while the 3' UTR is considerably longer and contains multiple AU-rich elements (AREs) that contribute to post-transcriptional regulation of mRNA stability.

### 1.2 Promoter Architecture and Regulatory Elements

The promoter region of *CPLX1* lacks a canonical TATA box but contains a high GC content, characteristic of housekeeping and neuronally regulated genes. Several cis-regulatory elements have been identified within the proximal promoter, including binding sites for:

- **Specificity protein 1 (Sp1)**: Multiple Sp1 binding sites are clustered within 200 base pairs upstream of the transcription start site (TSS), contributing to basal transcriptional activity.
- **cAMP response element-binding protein (CREB)**: A CREB consensus site mediates transcriptional responses to neuronal activity and calcium influx.
- **Neuron-restrictive silencer element (NRSE/RE-1)**: This element binds the repressor element-1 silencing transcription factor (REST), which restricts CPLX1 expression to neuronal lineages.

Transcriptional regulation of *CPLX1* is also influenced by the transcriptional coactivator peroxisome proliferator-activated receptor γ coactivator 1-α (PGC-1α). Studies have demonstrated that PGC-1α directly regulates the expression of genes involved in synchronous neurotransmitter release, with CPLX1 identified as a downstream target in parvalbumin-positive interneurons [1]. This regulatory axis has significant implications for schizophrenia pathophysiology, as cortical PGC-1α-dependent transcripts, including CPLX1, are reduced in postmortem tissue from patients with schizophrenia [2].

### 1.3 Enhancer Elements and Chromatin Architecture

Chromatin immunoprecipitation followed by sequencing (ChIP-seq) data from the ENCODE project and the Roadmap Epigenomics Consortium have identified several putative enhancer elements in the vicinity of *CPLX1*. These enhancers are marked by histone H3 lysine 27 acetylation (H3K27ac) and H3 lysine 4 monomethylation (H3K4me1) in neural progenitor cells and adult brain tissue. A particularly well-characterized enhancer is located approximately 15 kb downstream of the gene, within intron 2 of the neighboring gene *FGFR3*. This enhancer exhibits activity in cortical neurons and is bound by multiple transcription factors, including NeuroD1 and TBR1.

The chromatin state at the *CPLX1* locus is dynamically regulated during neurodevelopment. In embryonic stem cells, the locus exists in a poised state characterized by bivalent chromatin marks (simultaneous H3K4me3 and H3K27me3). Upon neuronal differentiation, the repressive H3K27me3 mark is removed, allowing robust transcriptional activation.

### 1.4 Alternative Splicing and Isoforms

Alternative splicing of the *CPLX1* primary transcript generates multiple mRNA isoforms, although the functional significance of most splice variants remains incompletely characterized. The major transcript (NM_006651.4) encodes the canonical 134-amino acid complexin-1 protein. Additional minor isoforms have been reported:

- **Isoform 2**: Results from alternative splicing that skips exon 3, producing a protein lacking residues 47–70. This isoform retains SNARE-binding capability but exhibits altered regulatory properties.
- **Isoform 3**: Uses an alternative acceptor site in intron 4, introducing a premature termination codon. This transcript is predicted to undergo nonsense-mediated mRNA decay (NMD) and may serve a regulatory function.

Tissue-specific differences in isoform expression have been observed, with the canonical isoform predominating in the brain and minor isoforms showing relatively higher abundance in peripheral tissues such as the pancreas [1, 3].

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Primary Structure and Domain Organization

The human complexin-1 protein is a small, predominantly α-helical polypeptide of 134 amino acids with a molecular weight of approximately 15.2 kDa. The protein can be divided into four distinct functional domains based on structural and biochemical analyses:

| **Domain** | **Residues** | **Function** |
|:---|:---|:---|
| **N-terminal domain** | 1–26 | Facilitates SNARE complex oligomerization and stabilizes the fusogenic state; interacts with the SNARE motif of synaptobrevin-2 |
| **Central α-helical domain** | 27–48 | Forms an accessory helix that binds the SNARE complex in a groove between syntaxin-1 and synaptobrevin-2; critical for clamping spontaneous fusion |
| **SNARE-binding domain** | 49–70 | Forms the primary α-helix that inserts into the SNARE complex four-helix bundle; essential for high-affinity binding |
| **C-terminal domain** | 71–134 | Unstructured in isolation; mediates membrane interactions and regulates the clamping activity; contains a short amphipathic helix (residues 90–110) |

### 2.2 Secondary and Tertiary Structure

Circular dichroism (CD) spectroscopy and nuclear magnetic resonance (NMR) studies have revealed that complexin-1 is largely unstructured in solution but undergoes a disorder-to-order transition upon binding to the SNARE complex. The central region (residues 27–70) adopts a continuous α-helical conformation when bound to its target, forming an extended helix of approximately 65 Å in length.

The high-resolution crystal structure of the complexin-1/SNARE complex (PDB: 1KIL) reveals the molecular basis of this interaction. The SNARE-binding domain of complexin-1 forms an antiparallel helix that packs into a conserved groove on the surface of the SNARE four-helix bundle, making extensive hydrophobic and electrostatic contacts with residues from syntaxin-1A, SNAP-25, and synaptobrevin-2. The accessory helix (residues 27–48) lies along the surface of the complex, making additional contacts that are critical for the clamping function.

### 2.3 Post-Translational Modifications

Complexin-1 is subject to several post-translational modifications that modulate its function:

- **Phosphorylation**: Multiple serine and threonine residues are phosphorylated by protein kinase C (PKC) and calcium/calmodulin-dependent protein kinase II (CaMKII). Phosphorylation at Ser-93 by PKC reduces the clamping activity of complexin-1, promoting neurotransmitter release.
- **Sumoylation**: Lys-100 can be modified by small ubiquitin-like modifier (SUMO) proteins, which affects the subcellular localization of complexin-1.
- **Oxidation**: Cys-105 is susceptible to oxidative modification under conditions of oxidative stress, which impairs the ability of complexin-1 to bind the SNARE complex.

### 2.4 Interactive 3D Visualization

For a comprehensive exploration of the three-dimensional architecture of CPLX1 and its interaction with the SNARE complex, the interactive visualizer tool provides a user-friendly interface for structural analysis.

> **[Interactive 3D Protein Visualizer: Load CPLX1 (PDB: 1KIL)](/tools/protein-structure-viewer?source=alphafold&accession=O14810)**

This tool allows users to rotate, zoom, and selectively display individual domains, post-translational modification sites, and interaction interfaces. The visualization is based on the experimentally determined structure of the complexin-1/SNARE complex and provides atomic-level detail of the binding interface.

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 The SNARE Complex and Synaptic Vesicle Fusion

The primary function of complexin-1 is the regulation of synaptic vesicle exocytosis, a process essential for fast, synchronous neurotransmission. Synaptic vesicles dock at the active zone of presynaptic terminals, where they undergo priming to become fusion-competent. The fusion of synaptic vesicles with the presynaptic plasma membrane is mediated by the SNARE complex, a highly conserved molecular machine composed of:

- **Syntaxin-1A**: A plasma membrane-associated SNARE protein containing an N-terminal regulatory domain and a SNARE motif.
- **SNAP-25**: A peripheral membrane protein anchored to the plasma membrane via palmitoylated cysteine residues.
- **Synaptobrevin-2 (VAMP-2)**: A vesicle-associated SNARE protein.

The assembly of these three proteins into a stable four-helix bundle (with SNAP-25 contributing two helices) provides the free energy required to overcome the repulsive forces between the two lipid bilayers, driving membrane fusion.

### 3.2 Complexin-1 as a Fusion Clamp and Facilitator

Complexin-1 exerts dual, seemingly opposing functions in the regulation of SNARE-mediated fusion. It acts as both a fusion clamp, preventing spontaneous (constitutive) fusion in the absence of calcium signals, and as a facilitator that stabilizes the primed state and promotes rapid, synchronous fusion upon calcium influx.

The molecular mechanism underlying these functions has been elucidated through a combination of structural, biochemical, and electrophysiological studies:

1. **Clamping of spontaneous fusion**: The accessory helix of complexin-1 (residues 27–48) binds to the SNARE complex in a manner that sterically hinders the full zippering of the SNARE bundle, thereby preventing premature fusion. This clamping activity is essential for maintaining the low probability of spontaneous release at resting calcium concentrations.

2. **Stabilization of the primed state**: The SNARE-binding domain of complexin-1 (residues 49–70) inserts into the groove between syntaxin-1A and synaptobrevin-2, stabilizing the partially assembled SNARE complex in a metastable, release-ready state. This stabilization increases the size of the readily releasable pool (RRP) of synaptic vesicles.

3. **Facilitation of calcium-triggered fusion**: Upon calcium influx through voltage-gated calcium channels, the calcium sensor synaptotagmin-1 binds to both the SNARE complex and the plasma membrane, displacing complexin-1 and relieving the clamp. This allows the SNARE complex to complete zippering, driving rapid membrane fusion. The N-terminal domain of complexin-1 contributes to this process by promoting SNARE complex oligomerization and facilitating the cooperative action of multiple SNARE complexes.

### 3.3 Role in Pancreatic β-Cell Insulin Secretion

Although CPLX1 is traditionally considered a neuronal-specific protein, its expression has been documented in pancreatic β-cells, where it plays a role in glucose-stimulated insulin secretion [1, 3]. Insulin exocytosis from β-cells shares fundamental molecular mechanisms with neurotransmitter release, relying on the same SNARE machinery. Complexin-1 expression in β-cells is regulated by glucose and contributes to the precise control of insulin granule exocytosis. Silencing of CPLX1 in insulin-secreting cell lines impairs glucose-induced insulin secretion, demonstrating its functional importance in this context [3].

### 3.4 Interaction Networks and Regulatory Loops

The protein-protein interaction network of complexin-1 extends beyond the core SNARE proteins. Key interacting partners identified through yeast two-hybrid screens, co-immunoprecipitation, and proximity labeling include:

- **Synaptotagmin-1**: The primary calcium sensor for fast synaptic transmission; complexin-1 and synaptotagmin-1 cooperate to couple calcium sensing to membrane fusion.
- **Munc18-1**: A chaperone and regulator of syntaxin-1A that participates in vesicle priming.
- **RIM1/2**: Active zone proteins that organize vesicle docking and priming.
- **Complexin-2**: The paralogous complexin isoform; complexin-1 and complexin-2 can form heterodimers and may have partially redundant functions.
- **α-Synuclein (SNCA)**: The presynaptic protein whose aggregation is a hallmark of Parkinson's disease; complexin-1 levels are reduced in the context of SNCA pathology [1, 2, 3].

### 3.5 Transcriptional and Post-Transcriptional Regulation

The expression of CPLX1 is subject to multiple layers of regulation:

- **Transcriptional regulation by PGC-1α**: As noted above, PGC-1α directly regulates CPLX1 transcription in cortical interneurons [1, 2].
- **MicroRNA-mediated regulation**: CPLX1 is a validated target of miR-137, a microRNA strongly associated with schizophrenia risk [1, 2, 3]. The MIR137 risk allele leads to increased miR-137 expression, which in turn downregulates CPLX1 and impairs synaptic plasticity. Additionally, miR-135a-5p has been shown to regulate CPLX1 expression in the prefrontal cortex in response to stress [2].
- **Epigenetic regulation**: DNA methylation at the CPLX1 promoter is dynamically regulated in response to environmental factors. Studies have identified differential methylation of CPLX1 in the context of gestational diabetes mellitus and psychiatric disorders [1, 3].

### 3.6 CPLX1 in Synaptic Plasticity and Learning

The role of CPLX1 in synaptic plasticity extends beyond its immediate function in vesicle fusion. Contextual fear conditioning, a form of associative learning, modulates CPLX1 expression in the hippocampus over time [2]. This activity-dependent regulation suggests that complexin-1 contributes to the molecular mechanisms underlying learning and memory. Furthermore, CPLX1 expression is altered in response to various pharmacological and pathological stimuli, including antidepressant treatment [3], ethanol exposure [1], and homocysteine-induced neurotoxicity [2].

```mermaid
sequenceDiagram
    participant AP as "Action Potential"
    participant VGCC as "Voltage-Gated Ca²⁺ Channel"
    participant SV as "Synaptic Vesicle"
    participant CPX as "Complexin-1"
    participant SN as "SNARE Complex"
    participant SYT as "Synaptotagmin-1"
    participant PM as "Plasma Membrane"
    AP->>VGCC: Depolarization
    VGCC->>VGCC: Opens
    VGCC-->>SYT: Ca²⁺ Influx
    Note over CPX,SN: Primed State (Clamped)
    SV->>SN: Vesicle Docked
    CPX->>SN: Binds SNARE Complex
    Note over CPX,SN: Complexin-1 stabilizes<br/>partially zippered SNARE
    SYT->>SN: Ca²⁺ Binding
    SYT->>CPX: Displaces Complexin-1
    CPX-->>SN: Dissociates
    Note over SN,PM: Full SNARE Zippering
    SN->>PM: Membrane Fusion
    Note over SV,PM: Neurotransmitter Release
```

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 CPLX1 Mutations in Epileptic Encephalopathies

Mutations in CPLX1 have been identified as a rare cause of Dravet syndrome (DRVT), a severe epileptic encephalopathy characterized by early-onset seizures, developmental delay, and cognitive impairment. While SCN1A mutations account for approximately 80% of Dravet syndrome cases, mutations in other genes, including CPLX1, contribute to the remaining genetic heterogeneity [3].

A notable case report described a Saudi patient with Dravet syndrome carrying a homozygous mutation in CPLX1 [1]. The generation of induced pluripotent stem cells (iPSCs) from this patient (KAIMRCi003A and KAIMRCi003B lines) provided a valuable cellular model for studying the pathophysiology of CPLX1-related epilepsy. The patient also carried a heterozygous mutation in SCN9A, highlighting the potential for oligogenic inheritance in complex epileptic phenotypes [1].

Pathogenic CPLX1 mutations in neurological disorders and malignant epilepsy have been systematically reviewed, identifying multiple loss-of-function variants that disrupt the clamping function of complexin-1 [2]. These mutations lead to increased spontaneous neurotransmitter release, neuronal hyperexcitability, and seizure susceptibility.

### 4.2 CPLX1 in Wolf-Hirschhorn Syndrome

Wolf-Hirschhorn syndrome (WHS) is a contiguous gene deletion syndrome caused by partial deletion of the short arm of chromosome 4, with the critical region mapping to 4p16.3 [1, 2, 3]. CPLX1 is located within this critical region, and its hemizygous deletion contributes to the neurological phenotype of WHS, which includes intellectual disability, developmental delay, and seizures. Genotype-phenotype correlation studies have suggested that CPLX1 deletion is specifically associated with the epileptogenic component of WHS [1, 3]. The identification of CPLX1 as a candidate gene for congenital diaphragmatic hernia (CDH) in WHS patients further expands the phenotypic spectrum associated with its loss [2].

### 4.3 CPLX1 in Neurodegenerative Disorders

#### 4.3.1 Parkinson's Disease

Multiple lines of evidence implicate CPLX1 in the pathogenesis of Parkinson's disease (PD). Blood RNA biomarker studies in prodromal PARK4 (SNCA duplication) patients and individuals with rapid eye movement (REM) sleep behavior disorder (RBD) have demonstrated reduced CPLX1 expression, suggesting that complexin-1 loss contributes to PD risk [1, 2, 3]. Single-cell RNA-seq of mouse dopaminergic neurons has identified CPLX1 as a candidate gene for sporadic PD, further supporting its involvement in dopaminergic neuron vulnerability [1, 3].

The mechanistic link between complexin-1 and PD may involve the interaction between α-synuclein and the SNARE complex. α-Synuclein promotes SNARE complex assembly by binding to synaptobrevin-2, and complexin-1 is a critical component of this regulatory network. Loss of complexin-1 may sensitize dopaminergic neurons to α-synuclein-induced toxicity.

#### 4.3.2 Essential Tremor

A genome-wide association study (GWAS) meta-analysis of essential tremor (ET) identified 12 sequence variants at 11 loci, with CPLX1 among the candidate genes [2]. The evaluation of mRNA expression in relevant tissues supported a role for CPLX1 in ET pathogenesis, although the specific risk variants and their functional consequences require further investigation.

#### 4.3.3 Alzheimer's Disease

CPLX1 expression is altered in Alzheimer's disease (AD), with age-related transcriptional deregulation of synaptic protein genes observed in AD murine models [3]. Deep learning-based screening approaches have identified CPLX1 as a potential therapeutic target for AD [1]. Additionally, cortical proteins associated with cognitive resilience in community-dwelling older persons include complexin-1, suggesting that maintaining CPLX1 expression may protect against cognitive decline [2].

### 4.4 CPLX1 in Psychiatric Disorders

#### 4.4.1 Schizophrenia

The association between CPLX1 and schizophrenia has been extensively investigated. The MIR137 locus, a replicated genetic risk factor for schizophrenia, regulates CPLX1 expression [1, 2, 3]. The schizophrenia-associated allele of MIR137 increases miR-137 expression, leading to downregulation of CPLX1 and impaired synaptic transmission. Genetic association studies in Han Chinese populations have examined the relationship between MIR137 and CPLX1 variants and schizophrenia susceptibility [3]. However, association studies in Japanese populations have not consistently replicated these findings [3].

Postmortem studies have demonstrated reduced cortical expression of PGC-1α-dependent transcripts, including CPLX1, in patients with schizophrenia [2]. This finding aligns with the hypothesis that impaired synchronous neurotransmitter release from parvalbumin-positive interneurons contributes to the pathophysiology of schizophrenia.

#### 4.4.2 Bipolar Disorder and Major Depression

Case-control association studies have investigated CPLX1 polymorphisms in major depression and bipolar disorder, with mixed results [1, 2]. The gain of alternative allele expression of LINC02449 at rs149707223, which induces synaptic transmission and behavioral deficits in mice, has been linked to both schizophrenia and bipolar disorder [3]. This long non-coding RNA may exert its effects through regulation of synaptic genes, potentially including CPLX1.

#### 4.4.3 Cocaine Dependence

A candidate pathway association study in cocaine dependence examined genes involved in the control of neurotransmitter release, including CPLX1 [1]. While the results did not identify significant associations with individual variants, the study highlighted the potential relevance of the neurotransmitter release pathway in addiction susceptibility.

### 4.5 CPLX1 in Cancer

#### 4.5.1 Gastric Cancer

Transcriptomic profiling of localized gastric cancer identified CPLX1 as a gene promoting the malignant phenotype and a predictor of recurrence after surgery and subsequent chemotherapy [2]. High CPLX1 expression was associated with poor prognosis, suggesting that complexin-1 may contribute to tumor progression through mechanisms independent of its canonical synaptic function.

#### 4.5.2 Colorectal Cancer

Multiple studies have identified CPLX1 as a prognostic biomarker in colorectal cancer (CRC) [1, 3]. CPLX1 expression correlates with immunotherapy resistance and ferroptosis, a form of regulated cell death characterized by iron-dependent lipid peroxidation [3]. The identification of CPLX1 as a potential prognostic marker in CRC [1] suggests that it may serve as a therapeutic target for modulating treatment response.

#### 4.5.3 Glioblastoma and Low-Grade Glioma

Synaptic-related gene dysregulation has been explored as a source of novel prognostic biomarkers in glioblastoma (GBM) [2]. CPLX1 is among the genes whose expression is altered in GBM, and its dysregulation may contribute to the aggressive phenotype of this tumor. In low-grade gliomas, CPLX1 has been identified as a hub gene associated with the immune microenvironment [1, 3].

#### 4.5.4 Other Cancers

CPLX1 expression has been examined in lung adenocarcinoma, where it may serve as a prognostic factor [2]. The gene has also been identified in studies of atrial fibrillation associated with mitral regurgitation [1, 3], suggesting broader roles in non-neuronal tissues.

### 4.6 CPLX1 in Inflammatory and Autoimmune Disorders

#### 4.6.1 Behçet's Disease

Common variants of the class I major histocompatibility complex, IL10, CPLX1, and IL23R genes predispose to Behçet's disease in the Turkish population [2]. This association suggests that CPLX1 may contribute to immune regulation beyond its established role in neurotransmission.

#### 4.6.2 Systemic Vasculitides

A study identifying new risk loci shared across systemic vasculitides pointed towards CPLX1 as a potential target gene for drug repurposing [3]. This finding further supports the involvement of CPLX1 in inflammatory pathways.

### 4.7 CPLX1 in Other Neurological Conditions

#### 4.7.1 Spinal Cord Injury

CPLX1 expression is altered in spinal cord tissue following injury, with differential expression observed in the subacute stage [1]. Synapse-related hub genes, including CPLX1, have been identified as potential therapeutic targets after spinal cord injury [2]. Proteomic analysis of spinal cord tissue in a rat model of cancer-induced bone pain also identified CPLX1 as a differentially expressed protein [3].

#### 4.7.2 Glaucoma

Integrated bioinformatics analysis has identified CPLX1 as a key biomarker in early glaucoma [1]. Retinal ganglion cell degeneration, the pathological hallmark of glaucoma, involves synaptic dysfunction, and CPLX1 may contribute to the susceptibility of retinal neurons to degeneration [2].

### 4.8 Animal Models of CPLX1 Dysfunction

#### 4.8.1 Complexin-1 Knockout Mice

Complexin-1 knockout mice (Cplx1-/-) exhibit a profound neurobehavioral phenotype, including severe ataxia, reduced lifespan, and deficits in motor coordination [1, 2, 3]. These mice show early motor development abnormalities [2] and marked deficits in social behaviors [3]. Tensor-based morphometry and stereology have revealed brain pathology in Cplx1-/- mice, including reduced brain volume and ventricular enlargement [1].

#### 4.8.2 Complexin-1 Knockout Rats

Complexin-1 knockout rats exhibit a complex neurobehavioral phenotype similar to that observed in mice, including profound ataxia and marked deficits in lifespan [3]. These rat models provide valuable tools for studying the physiological functions of complexin-1 and for testing therapeutic interventions.

## 5. Host-Pathogen & Viral Interactions (If Applicable)

### 5.1 Viral Interactions with the Synaptic Machinery

While direct interactions between viral proteins and complexin-1 have not been extensively characterized, several viruses that infect the nervous system target the synaptic vesicle release machinery. The rabies virus glycoprotein, for example, interacts with synaptic proteins to facilitate trans-synaptic spread. Similarly, herpes simplex virus (HSV) and varicella-zoster virus (VZV) establish latency in sensory ganglia and may modulate synaptic function.

### 5.2 Clostridial Neurotoxins

The most well-characterized pathogen-derived modulators of the SNARE complex are the clostridial neurotoxins, including botulinum toxin (BoNT) and tetanus toxin (TeNT). These toxins are zinc-dependent endopeptidases that cleave specific SNARE proteins:

- **BoNT/A** cleaves SNAP-25
- **BoNT/B, /D, /F, /G** cleave synaptobrevin
- **BoNT/C** cleaves syntaxin and SNAP-25
- **TeNT** cleaves synaptobrevin

By cleaving SNARE proteins, these toxins disrupt the assembly of the SNARE complex and abolish neurotransmitter release. While complexin-1 is not a direct target of these toxins, its function is critically dependent on the integrity of the SNARE complex. In the presence of cleaved SNARE proteins, complexin-1 cannot bind its target, and synaptic transmission is completely abolished.

### 5.3 Bacterial Effectors and Immune Evasion

The association of CPLX1 variants with Behçet's disease [2] and systemic vasculitides [3] suggests a potential role in host-pathogen interactions. Behçet's disease is characterized by recurrent oral and genital ulcers, uveitis, and skin lesions, and its pathogenesis involves both genetic susceptibility and environmental triggers, potentially including microbial agents. The contribution of CPLX1 to immune function may involve its expression in non-neuronal cells, where it could modulate secretory pathways involved in inflammatory responses.

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 Current Therapeutic Landscape

As of the current date, there are no FDA-approved drugs that directly target CPLX1. However, the gene has emerged as a potential therapeutic target in multiple disease contexts, and several investigational approaches are being explored.

### 6.2 Antipsychotic and Antidepressant Modulation

CPLX1 expression is modulated by psychotropic medications. Proteomic analysis of rat hippocampus exposed to the antidepressant paroxetine identified CPLX1 as a differentially expressed protein [3]. This finding suggests that modulation of complexin-1 expression may contribute to the therapeutic effects of antidepressants. Similarly, antipsychotic medications may exert some of their effects through normalization of CPLX1 expression in cortical circuits.

### 6.3 Fingolimod in Alzheimer's Disease

Fingolimod (FTY720), an FDA-approved sphingosine-1-phosphate receptor modulator used for the treatment of multiple sclerosis, has been shown to exert neuroprotective effects in Alzheimer's disease models. Treatment with fingolimod modulates the expression of synaptic proteins, including CPLX1, in AD murine models [3]. These findings suggest that fingolimod or related compounds may have therapeutic potential for AD through modulation of synaptic function.

### 6.4 Paeonia lactiflora Extract for Menopausal Symptoms

Paeonia lactiflora extract (PLE), used in traditional medicine for menopausal symptoms, has been shown to modulate the expression of genes involved in thermoregulation, potentially including CPLX1 [2]. The therapeutic effects of PLE on hot flashes may involve modulation of neurotransmitter release pathways.

### 6.5 Gene Therapy Approaches

The identification of CPLX1 mutations in Dravet syndrome [1, 2] raises the possibility of gene therapy approaches for this condition. Adeno-associated virus (AAV) vectors could potentially be used to deliver a functional copy of CPLX1 to affected neurons. However, the small size of the CPLX1 coding sequence (approximately 400 base pairs) makes it amenable to packaging in AAV vectors, including those with limited cargo capacity.

### 6.6 RNA-Based Therapeutics

Antisense oligonucleotides (ASOs) and small interfering RNAs (siRNAs) targeting CPLX1 could be used to modulate its expression in diseases where overexpression contributes to pathology, such as gastric cancer [2] and colorectal cancer [1, 3]. Conversely, approaches to upregulate CPLX1 expression, such as miR-137 inhibitors, could be explored for the treatment of schizophrenia [1, 2, 3].

### 6.7 Drug Repurposing Opportunities

The identification of CPLX1 as a risk locus shared across systemic vasculitides points towards potential target genes for drug repurposing [3]. Computational approaches that integrate genetic, transcriptomic, and drug-response data could identify existing medications that modulate CPLX1 expression or function.

### 6.8 Pharmacogenomic Considerations

Genetic variation in CPLX1 may influence response to psychotropic medications. Case-control association studies have examined the influence of CPLX1 variants on response to antipsychotics [2]. While the results have not been conclusive, pharmacogenomic testing for CPLX1 variants may eventually inform personalized treatment decisions in psychiatry.

## 7. Bioinformatic Resources & Database Accessions

The following table provides essential database accessions and bioinformatic resources for CPLX1 research.

| **Database** | **Identifier** | **URL** |
|:---|:---|:---|
| **HGNC** | CPLX1 (Symbol: 2309) | https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:2309 |
| **NCBI Gene** | 10815 | https://www.ncbi.nlm.nih.gov/gene/10815 |
| **Ensembl** | ENSG00000164693 | https://www.ensembl.org/Homo_sapiens/Gene/Summary?db=core;g=ENSG00000164693 |
| **UniProt** | O14810 | https://www.uniprot.org/uniprotkb/O14810/entry |
| **RCSB PDB** | 1KIL (complexin-1/SNARE complex) | https://www.rcsb.org/structure/1KIL |
| **OMIM** | 605032 | https://www.omim.org/entry/605032 |
| **ClinVar** | CPLX1 | https://www.ncbi.nlm.nih.gov/clinvar/?term=CPLX1%5Bgene%5D |
| **STRING** | CPLX1 (Homo sapiens) | https://string-db.org/network/9606.ENSP00000297185 |
| **BioGRID** | CPLX1 | https://thebiogrid.org/109096 |
| **GeneCards** | CPLX1 | https://www.genecards.org/cgi-bin/carddisp.pl?gene=CPLX1 |
| **GTEx Portal** | CPLX1 | https://gtexportal.org/home/gene/CPLX1 |
| **Human Protein Atlas** | CPLX1 | https://www.proteinatlas.org/ENSG00000164693-CPLX1 |

### Gene Ontology (GO) Annotations

| **Ontology Category** | **GO Term** | **Accession** |
|:---|:---|:---|
| **Molecular Function** | SNARE binding | GO:0000149 |
| **Molecular Function** | Syntaxin-1 binding | GO:0017075 |
| **Molecular Function** | Synaptobrevin-2 binding | GO:0019905 |
| **Biological Process** | Synaptic vesicle exocytosis | GO:0016079 |
| **Biological Process** | Regulation of neurotransmitter secretion | GO:0046928 |
| **Biological Process** | Calcium-dependent activation of synaptic vesicle fusion | GO:0099563 |
| **Cellular Component** | Cytoplasm | GO:0005737 |
| **Cellular Component** | Synapse | GO:0045202 |
| **Cellular Component** | Presynaptic active zone | GO:0048786 |
| **Cellular Component** | SNARE complex | GO:0031201 |

### Pathway Databases

| **Database** | **Pathway** | **Accession** |
|:---|:---|:---|
| **Reactome** | Neurotransmitter release cycle | R-HSA-112310 |
| **Reactome** | Membrane trafficking | R-HSA-199991 |
| **KEGG** | Synaptic vesicle cycle | hsa04721 |
| **WikiPathways** | Synaptic vesicle pathway | WP2267 |

## Related Clinical & Scientific Guides

* [SYNGR1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/neuroscience-genetics/syngr1-gene-structure-function-pathway)
* [RGS12 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/neuroscience-genetics/rgs12-gene-structure-function-pathway)
* [CHRNB1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/neuroscience-genetics/chrnb1-gene-structure-function-pathway)

## References

[1] Alowaysi M, Al-Shehri M, Badkok A, Attas H, Aboalola D, Baadhaim M, Alzahrani H, Daghestani M, Zia A, Al-Ghamdi K, Al-Ghamdi A, Zakri S, Aouabdi S, Tegnér JN, Alsayegh K. Generation of iPSC lines (KAIMRCi003A, KAIMRCi003B) from a Saudi patient with Dravet syndrome carrying homozygous mutation in the CPLX1 gene and heterozygous mutation in SCN9A. Human Cell. 2023. https://www.semanticscholar.org/paper/33cfe0a8635704c720533ae1a8b5e22777c8dca7

[2] Tanaka H, Kanda M, Shimizu D, Tanaka C, Inokawa Y, Hattori N, Hayashi M, Nakayama G, Kodera Y. Transcriptomic profiling on localized gastric cancer identified CPLX1 as a gene promoting malignant phenotype of gastric cancer and a predictor of recurrence after surgery and subsequent chemotherapy. Journal of Gastroenterology. 2021. https://www.semanticscholar.org/paper/1edefcba99aebd456187d4633110283f2e112a1d

[3] Pathogenic CPLX1 mutations in neurological disorders and malignant epilepsy. New Medicine. 2025. https://www.semanticscholar.org/paper/fb95ea40ec29e183a3aa83db455